PV Bulletin

Chenodeoxycholic Acid Leadiant Labeling Update

Summary of the European public assessment report (EPAR) for Chenodeoxycholic acid Leadiant.

Primary source: View

PV Impact Brief

Urgency: HighConfidence: high

What changed

Labeling updates have been made to the Chenodeoxycholic acid Leadiant product information based on recent assessments regarding its safety and efficacy.

Why it matters

The labeling update ensures that healthcare providers have the latest information regarding the usage, benefits, and potential risks associated with Chenodeoxycholic acid Leadiant, especially given its orphan drug status.

Action needed

Annual reviews of new information will be conducted to update the summary, requiring continuous monitoring and data submission in response to findings.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Annual review

Evidence and confidence

Confidence: highSource updated: Aug 24, 2026

Full briefing

Practical implication

Annual reviews of new information will be conducted to update the summary, requiring continuous monitoring and data submission in response to findings.

Chenodeoxycholic acid Leadiant, previously known as Chenodeoxycholic acid sigma-tau, has undergone a regulatory change following the summary of the European public assessment report which details its approval for use within the EU for treating cerebrotendinous xanthomatosis.

What changed: Labeling updates have been made to the Chenodeoxycholic acid Leadiant product information based on recent assessments regarding its safety and efficacy.

Why it matters: The labeling update ensures that healthcare providers have the latest information regarding the usage, benefits, and potential risks associated with Chenodeoxycholic acid Leadiant, especially given its orphan drug status.

Practical implication: Annual reviews of new information will be conducted to update the summary, requiring continuous monitoring and data submission in response to findings.

View original source

  • Source: EMA - What's new RSS
  • Published at source: 2026-08-24T00:00:00.000Z
  • Discovered by monitor: 2026-08-24T22:37:52.950Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Labeling#Safety Signals#Source-ingestion#Regulator-monitor#European Union#Ema.europa.eu

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward